Clay Siegall Is More Than A Doctor

Home | Cancer Research | Clay Siegall Is More Than A Doctor

Are you interested in cancer research? Have you ever heard of Seattle Genetics? Seattle Genetics is by far one of the best biotech companies in the world that specializes in fighting cancer. The company is located in Bothell, Washington, and it has up to 1,000 employees. Developing and commercializing antibody-drug conjugates is big-business, but all cancer research companies aren’t the same. Great companies tend to have great leadership and this is what separates Seattle Genetics from the pack. Dr. Clay Siegall comes in the form of chief executive officer as well as the president. He has been in the business for over three decades, and he has worked with the best-of-the-best.

Since the birth of Seattle Genetics in 1998, Siegall has been on a never-ending quest to fight cancer. Unlike the medications of the past that used radical treatments, Seattle Genetics use some of the most innovative antibody-drug conjugates. These advanced drugs are targeted because they will attach themselves to cancer cells in the body without harming any of the good cells. This drastically cuts down on unwanted side effects, which can be even more sickening than the disease itself. Siegall is a strong believer of scientific innovation, drug development and rigorous research. “The company didn’t become profitable until 10 years after its IPO’s inception,” said Siegall. As of today, Seattle Genetics earn revenue from licensing its technologies, by selling its proprietary medications and from production partnerships.

In the years of 1999 and 2000, the company was going through generated-revenue fairly quickly. This action caused Seattle Genetics to batten down the hatches by employing a dynamic sales team. This sales team had extensive knowledge in business as well as biotechnology. This important face of the company began to close many six-figure deals, which pulled the company back from the black. Dr. Clay Siegall is in full-control of the company’s destiny and many more things are expected in the near future.